MERCK KGAA
Heather Connor
+1 - 978-294-1660
• Program combines grants portfolio with annual €20 million investment to advance innovation and medical education
Darmstadt, Germany, July 8, 2014 - Merck Serono, the biopharmaceutical division of Merck, today announced the launch of Merck Global Grants - a program that underscores the company's commitment to funding scientific innovation and independent medical education around the world. The initiative encompasses Merck Serono's complete grants portfolio, including the Grants for Innovation in Research and Grants for Independent Medical Education.
The program totals an annual investment of €20 million across all grants programs, highlighting the company's efforts to promote advances in the field of medicine, addressing recognized gaps in healthcare knowledge, and improving the quality of patient care.
"Merck Serono has a long-standing reputation as a strong advocate for scientific innovation and medical education, believing that both are integral to helping healthcare professionals bring enhanced care to patients," said Steven Hildemann, Global Chief Medical Officer and Head of Global Medical and Safety at Merck Serono.
The Grants for Innovation in Research identify and fund promising research from across biopharma, including academia, research centers, smaller start-ups and independent researchers. Specific grants focus on areas in which Merck Serono has a
Page 1 of 2
Merck KGaA www.merckserono.com Merck Serono is a division of Merck. Frankfurter Strasse 250
64293 Darmstadt
Germany
Hotline +49 (0) 6151 72-5000 www.merckgroup.com
Tel. +1-978-294-1660 heather.connor@emdserono.com
strong R&D and commercial presence, including the Grant for Oncology Innovation, Grant for Multiple Sclerosis Innovation, Grant for Fertility Innovation, and Grant for Growth Innovation.
The Grants for Independent Medical Education foster the advancement of medicine, and address recognized gaps in healthcare knowledge, in order to improve patient care. The program includes the launch of an online portal which allows highly transparent and ethical interactions with medical education providers and represents an important milestone in the Merck Serono Medical Education Strategy. Funding is provided to educational institutions such as universities, medical education providers, medical scientists and scientific organizations.
To review eligibility requirements or apply for a grant, visit www.merck-grants.com.
Merck Serono is the biopharmaceutical division of Merck. With headquarters in Darmstadt, Germany, Merck Serono offers leading brands in 150 countries to help patients with cancer, multiple sclerosis, infertility, endocrine and metabolic disorders as well as cardiovascular diseases. In the United States and Canada, EMD Serono operates as a separately incorporated subsidiary of Merck Serono.
Merck Serono discovers, develops, manufactures and markets prescription medicines of both chemical and biological origin in specialist indications. We have an enduring commitment to deliver novel therapies in our core focus areas of neurology, oncology, immuno-oncology and immunology.
For more information, please visit www.merckserono.com.
All Merck Press Releases are distributed by e-mail at the same time they become available on the Merck Website. Please go to www.merckgroup.com/subscribeto register online, change your selection or discontinue this service.
Merck is a leading company for innovative and top-quality high-tech products in the pharmaceutical and chemical sectors. With its four divisions Merck Serono, Consumer Health, Performance Materials and Merck Millipore, Merck generated total revenues of € 11.1 billion in 2013. Around 38,000 Merck employees work in 66 countries to improve the quality of life for patients, to further the success of customers and to help meet global challenges. Merck is the world's oldest pharmaceutical and chemical company - since
1668, the company has stood for innovation, business success and responsible entrepreneurship. Holding an approximately 70 percent interest, the founding family remains the majority owner of the company to this day. Merck, Darmstadt, Germany is holding the global rights to the Merck name and brand. The only exceptions are Canada and the United States, where the company is known as EMD.
Page 2 of 2
|
distributed by
|
